Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death and new therapies are urgently required to treat this disease. Recent data suggest that the FGF 19‐FGFR 4 axis may be a key driver in certain forms of HCC, making the pathway an interesting, emerging molecular target for potential therapeutic intervention. A complication is that, outside of malignant disease, FGFR 4 plays an important physiological role in the regulation of hepatic bile acid (BA) synthesis. FGF 19 signalling via FGFR 4 suppresses de novo BA production in the liver, tightly maintaining hepatic and systemic levels of these detergent‐like molecules at a physiological threshold and preventing pathological complications of raised BA levels, such as cholestatic liver injury and bile acid diarrhoea. In some cases of HCC, the malignant disease causes bile duct obstruction, preventing BA secretion from the liver and resulting in cholestasis. Here, the role of FGFR 4 signalling in both HCC and BA homoeostasis is discussed. The potential effects of therapeutic FGF 19‐FGFR 4 inhibition on human hepatobiliary/gastrointestinal physiology are considered along with the potential safety implications of FGF 19‐FGFR 4 blockade in patients with HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748
Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0142 · Cited by 700
Tomlinson, E., Fu, L., John, L., Hultgren, B., Huang, X., Renz, M., Stephan, J. P., Tsai, S. P., Powell-Braxton, L., French, D., et al. (2002) · Endocrinology · doi:10.1210/endo.143.5.8850 · Cited by 576
A Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359 · cited 1×
“FGF19 clearly has mitogenic potential, as transgenic mice overexpressing FGF19 in skeletal muscle (FGF19-mice) have been observed to develop HCC (11).”
BackgroundMiura, S., Mitsuhashi, N., Shimizu, H., Kimura, F., Yoshidome, H., Otsuka, M., Kato, A., Shida, T., Okamura, D., & Miyazaki, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-56 · Cited by 193
Cited by
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924
Singh, S., Grabner, A., Yanucil, C., Schramm, K., Czaya, B., Krick, S., Czaja, M. J., Bartz, R., Abraham, R., Di Marco, G. S., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.05.019 · Cited by 360
Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14109 · Cited by 298
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227
“Endogenous FGF19 and fibroblast growth factor receptor 4 (FGF4R) have been implicated in the development of HCC (and even some extrahepatic cancers), and inhibitors of FGF4R signaling have been proposed as anticancer treatment.((50)) In humans, FGF19 is amplified in HCC,((51)) and in mice, ectopic overexpression of FG…”
Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000131 · Cited by 127
Metadata
- Authors
- Mellor, H. R.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2014-01-24
- Volume
- 34
- Issue
- 6
- Pages
- e1-9
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2026944977
- Cited by
- 45
- References
- 6
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations. https://app.cochat.ai/papers/10.1111/liv.12462
- The paper
- Mellor, H. R. (2014). Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations. Liver International. https://doi.org/10.1111/liv.12462
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.